glp 1 vs sglt2 weight loss variability with inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities - Brown - 2019 - Obesity Reviews Liver gains beyond glycemic control:

A., Sawaya, M

New GLP1-based multi-agonist therapies seem to be substantially more effective than older GLP1R agonists in reducing body weight but their safety requires ongoing scrutiny in trials assessing outcomes in individuals with obesity

Pappas in the Journal of Vascular Surgery: Venous and Lymphatic Disorders found that treatment outcomes for chronic venous disease improve as BMI decreases, and that higher BMI is independently associated with poorer results after venous procedures

Back Hall, K (11 Jan 2022) 'The discovery of insulin: a story of monstrous egos and toxic rivalries', The Conversation

PMID: 26371721